Indirect comparison between immunotherapy alone and immunotherapy plus chemotherapy as first-line treatment for advanced non-small cell lung cancer: a systematic review

OBJECTIVES: Use of immune checkpoint inhibitors as first-line treatment for advanced (stage IIIB/IV) non-small cell lung cancer (NSCLC) remains controversial. Clinical trials comparing single-drug immunotherapy (IO) with immunotherapy plus chemotherapy (IC) are lacking. We aimed to compare the effic...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Lingling, Xu, Fei, Chen, Yu, Ren, Xiaoli, Liu, Yu, Chen, Yuan, Xia, Shu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7682470/
https://www.ncbi.nlm.nih.gov/pubmed/33444168
http://dx.doi.org/10.1136/bmjopen-2019-034010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7682470/
https://www.ncbi.nlm.nih.gov/pubmed/33444168
http://dx.doi.org/10.1136/bmjopen-2019-034010

Ejemplares similares